ARHGEF2

Across TCGA pan-cancer cohorts, ARHGEF2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARHGEF2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARHGEF2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where ARHGEF2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.812	<.001	12	view →
HNSC	Male	IV	+0.433	<.001	11	view →
COAD	Female	III,IV	+0.223	<.001	10	view →
PDAC	Female	All	+0.530	<.001	9	view →
LSCC	Female	All	−0.232	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARHGEF2–CCRCC

Open the CCRCC breakdown →